300122 Chongqing Zhifei Biological Products
- 28.38
- -0.05-0.18%
Chongqing Zhifei Biological Products News
Zhifei Biotech (300122): 24Q3 performance under pressure awaiting vaccine release
Zhifei Biotech (300122): 24Q3 product sales continue to advance under short-term pressure self-development pipeline
Zhifei Biotech (300122): Short performance, sales of shingles vaccine continue to advance under pressure
Zhifei Biology (300122): The HPV vaccine is sold under pressure and the herpes vaccine is expected to be gradually released
Zhifei Biotech (300122): Actively strengthening sales capacity building and anticipating a month-on-month improvement in product sales
Zhifei Biotech (300122): Exploring the inflection point of Zhifei Biotech's business with three questions and three answers
Zhifei Biotech (300122): Exploring the inflection point of Zhifei Biotech's business with three questions and three answers
Research Nuggets丨Tianfeng Securities: Maintaining Zhifei Biotech's “Buy” Rating and Sales of Recombinant Herpes Vaccine Is Worth Looking Forward to
Zhifei Biotech (300122): Steady growth in recombinant shingles vaccine sales in 2023 is worth looking forward to
Research Report Nuggets丨CITIC Construction Investment: Zhifei Biotech's shingles vaccine contributed new volume and maintained a “buy” rating
Zhifei Biotech (300122): The existing business is steady and far reaching new contributions to the shingles vaccine
Zhifei Biotech (300122): HPV vaccine enters steady growth period, focus on shingles vaccine dosage
Zhifei Biotech (300122): Performance during the reporting period was slightly lower than expected, “Self-developed & Agency” dual-drive built a long-term growth engine for performance
Zhifei Biotech (300122): Nine valent HPV accelerates the release of shingles and opens up room for growth
Zhifei Biotech (300122): HPV vaccine continuous release development pipeline enters harvest period
Zhifei Biotech (300122): Further release of the HPV vaccine, and the shingles vaccine will soon contribute new doses
Zhifei Biotech (300122): Changes in agent product structure expected to release shingles vaccine
Zhifei Biotech (300122) Annual Report Review Report: Company fundamentals, high quality growth, high certainty, and shingles are expected to create a second growth curve
Zhifei Biotech (300122) Company Comment: Proposed repurchase of 300 to 500 million yuan of company shares shows confidence in long-term development
Zhifei Biotech (300122): “Double Improvement of Quality and Return” Program Boosts Confidence in Stable Development
Analysis
Price Target
No Data
No Data